Promega signed a license agreement with BrainXell, a Madison-based producer of iPSC-derived human cells such as neurons and glia, the company announced today. “Reporter-enabled human neural models take expertise that…

BrainXell is launching its human induced pluripotent stem cell (iPSC)-derived sensory neurons, the company announced recently. According to a release, the iPSC-derived sensory neurons are a scalable human cellular platform…

BrainXell Therapeutics announced recently preclinical data demonstrating the efficacy of its neuronal therapy called BXT-110 as a potential disease-modifying treatment for Parkinson’s disease. BrainXell Therapeutics is using induced pluripotent stem…